Women with advanced estrogen receptor-positive (ER-positive) breast cancer now have a new treatment option at their disposal. The FDA recently approved a drug called palbociclib (Ibrance®) as a frontline treatment for women with ER-positive, HER2-negative metastatic breast cancer.
First Annual CRC Charity Golf Tournament
The Importance of Breast Cancer Research: proceeds of the first Cancer Research Collaboration Charity (CRC) Golf Tournament will be used to support ongoing efforts of the CRC and its partners to fight cancer.
Recent research into modern breast cancer therapies have driven major breakthroughs in antibody-drug conjugates, or “smart drugs,” which work by targeting cancer cells while minimizing damage to healthy body tissue.
Kadcyla, also known ado-trastuzumab emtansine (T-DM1), is one of the latest “smart drugs” to be FDA-approved in the treatment of women diagnosed with metastatic HER2-positive breast cancer. Kadcyla may also have potential as therapy after surgery where intent is curative.
Kadcyla, approved by the U.S. Food and Drug Administration (FDA) in February 2013, is one of the latest advancements to improve our ability to treat breast cancer.